EMA launches important initiative for the implementation of NAMs in Europe 

The Voluntary Data Submission (VDS) Pilot recently launched by the European Medicines Agency (EMA) may prove to be one of the most important regulatory initiatives for the future adoption of New Approach Methodologies (NAMs) in Europe 

Why? 

Because innovative technologies do not become regulatory standards simply because they are published in scientific journals or presented at conferences. 

Regulators need opportunities to review, evaluate, and build confidence in real-world data. 

That is exactly what EMA's new pilot aims to achieve. 

The initiative creates a structured framework allowing companies, method developers, CROs, and academic laboratories to voluntarily submit data covering organoids, microphysiological systems, organ-on-chip models, computational approaches, and integrated NAM strategies outside of a marketing authorization application.  

Selected participants will receive individual, non-binding, non-decisional feedback from experts across the European medicines regulatory network, helping regulators gain experience with these technologies while providing developers with valuable insight into regulatory expectations.  

Why This Matters 

By increasing regulatory acceptance of NAMs and strengthen the scientific dialogue between developers and regulatorsthe EMA effectively will support the fact that the future of NAM adoption will not be driven by promises. It will be driven by evidence. 

As an organoid expert from its beginning, I strongly welcome and support this initiative. 

Abc biopply as Europe's first fully integrated Organoid CRO, has generated strong evidence through 25+ peer-reviewed publications and countless preclinical studies based on its proprietary 3D CoSeedis™ Humanized Multi-Organoid Models based on the unique 3D CoSeedis in chip Technology™. Nevertheless, we are convinced that the future belongs to an integrated fit-for-purpose principle, using dedicated models to answer dedicated questions. The goal is not to replace one model with another. It is to generate the most predictive and IND-relevant data by using the right model for the right question. 

The EMA pilot is a significant milestone toward making this vision a reality in Europe and elsewhere.